CDMOs offering Cell-Line Development with Antibody-Drug Conjugate (ADC)
11 published
11 published CDMOs match Cell-Line Development and Antibody-Drug Conjugate (ADC).
Locations in this set include United States, China, Germany, Japan, United Kingdom, and Denmark.
Capabilities that show up most often in this set: ADC (Antibody-Drug Conjugate) Manufacturing, CMC Analytical Development, Monoclonal Antibody (mAb) Manufacturing, Process Development, and Recombinant Protein Manufacturing.
Matching companies
AGC BiologicsGlobal CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
AbzenaFully integrated biologics and bioconjugates CDMO+CRO offering drug design, development, and GMP manufacturing for antibodies, ADCs, AOCs, RDCs, and vaccines from discovery through commercial scale.
Altruist BiologicsGlobal CDMO offering end-to-end development and GMP manufacturing for monoclonal antibodies, bispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates, with facilities in Suzhou and Hangzhou featuring up to 20,000-liter bioreactors.
Avid BioservicesAvid Bioservices is a U.S.-based mammalian cell culture CDMO providing integrated process development, analytical development, and CGMP biologics manufacturing from DNA to IND to commercial supply, with 30+ years of expertise and FDA-inspected facilities in California.
CelonicSwiss-based pure-play biologics CDMO specializing in next-generation bioprocessing technologies including process intensification and full perfusion to reduce cost of goods for biotech and biosimilar clients.
IcosagenIcosagen is an integrated CRDMO (Contract Research, Development & Manufacturing Organization) specializing in antibody discovery, protein production, cell line development, and GMP manufacturing for biologics programs from discovery through commercial scale.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.- STC BiologicsBoutique biologics CDMO with a Speed-to-Clinic platform spanning royalty-free cell line development through cGMP drug substance, in as little as 12 months. Runs a single-use mammalian GMP suite in Newton, MA for antibody, bispecific, and ADC programs.
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Wheeler BioOklahoma-based CDMO specializing in antibody-based therapeutics from cell line development through cGMP manufacturing. Offers ModularCMC platform with phase-appropriate work packages and high-touch project management.
Markdown mirror: /explore/cell-line-development/antibody-drug-conjugate.md